To date, no clinical trials having MEK1/2-mutated melanoma patients as population of interest are ongoing but, as we mentioned before, MEK inhibitors are being tested in several studies, alone or in combination with other drugs, and their use with BRAF inhibitors has become a standard in the therapy of BRAF mutated metastatic melanoma. This evidence concerns the gene MAP2K7 and melanoma.